Page 17 - Read Online

Page 12 of 12 Pedica et al. Hepatoma Res 2021;7:71 https://dx.doi.org/10.20517/2394-5079.2021.89

identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;19:2878-80. DOI PubMed PMC
23. Saborowski A, Lehmann U, Vogel A. FGFR inhibitors in cholangiocarcinoma: what's now and what's next? Ther Adv Med Oncol
2020;12:1758835920953293. DOI PubMed PMC
24. Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies
correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 2021;11:326-39. DOI PubMed
25. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov
2013;3:636-47. DOI PubMed PMC
26. Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations
that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov 2021;11:2488-505. DOI PubMed
27. Lee K, Song YS, Shin Y, et al. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes
and their clinicopathological features. Sci Rep 2020;10:15820. DOI PubMed PMC
28. Goyal L, Govindan A, Sheth RA, et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate
dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist 2015;20:1019-27. DOI PubMed PMC
29. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma
identified through broad-based tumor genotyping. Oncologist 2012;17:72-9. DOI PubMed PMC
30. Brat DJ, Verhaak RG, Aldape KD, et al; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of
diffuse lower-grade gliomas. N Engl J Med 2015;372:2481-98. DOI PubMed PMC
31. Demols A, Rocq L, Charry M, et al. NTRK gene fusions in biliary tract cancers. J Clin Oncol 2020;38:574. DOI
32. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res 2018;24:5807-14. DOI
PubMed
33. Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice
and clinical research. Ann Oncol 2019;30:1417-27. DOI PubMed
34. Ju JY, Dibbern ME, Mahadevan MS, Fan J, Kunk PR, Stelow EB. Mismatch repair protein deficiency/microsatellite instability is rare
in cholangiocarcinomas and associated with distinctive morphologies. Am J Clin Pathol 2020;153:598-604. DOI PubMed
35. Goeppert B, Roessler S, Renner M, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver
fluke associated cholangiocarcinoma. Br J Cancer 2019;120:109-14. DOI PubMed PMC
36. Marin JJG, Prete MG, Lamarca A, et al; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European
Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary
cancer. Br J Cancer 2020;123:1047-59. DOI PubMed PMC
37. Loeuillard E, Yang J, Buckarma E, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells
augments PD-1 blockade in cholangiocarcinoma. J Clin Invest 2020;130:5380-96. DOI PubMed PMC
38. Spizzo G, Puccini A, Xiu J, et al. Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden
(TMB) and microsatellite instability (MSI). J Clin Oncol 2019;37:4085. DOI
39. Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. DOI
PubMed PMC
40. Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract
cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol 2014;27:1028-34. DOI PubMed
41. Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin
Oncol 2018;36:276-82. DOI PubMed PMC
42. Albrecht T, Rausch M, Rössler S, et al. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated
cholangiocarcinogenesis. BMC Cancer 2019;19:1191. DOI PubMed PMC
43. Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50. DOI
PubMed
44. Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol
2020;73:315-27. DOI PubMed PMC
45. Cadamuro M, Lasagni A, Lamarca A, et al. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical
development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. DOI PubMed PMC
46. 33rd European congress of pathology - abstracts. Virchows Arch 2021;479:1-320. DOI
47. Chang TT, Cheng JH, Tsai HW, Young KC, Hsieh SY, Ho CH. Plasma proteome plus site-specific N-glycoprofiling for hepatobiliary
carcinomas. J Pathol Clin Res 2019;5:199-212. DOI PubMed PMC
48. Francaviglia I, Magliacane G, Lazzari C, et al. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA
in lung cancer patients. Lung Cancer 2019;134:225-32. DOI PubMed
49. Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver matrix in benign and malignant biliary tract disease. Semin Liver
Dis 2020;40:282-97. DOI PubMed
50. Park DD, Phoomak C, Xu G, et al. Metastasis of cholangiocarcinoma is promoted by extended high-mannose glycans. Proc Natl Acad
Sci U S A 2020;117:7633-44. DOI PubMed PMC